OCULAR THERAPEUTIX, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that OCULAR THERAPEUTIX, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $504.0K | Mar 7, 2019 |
| FY2018 | Sep 30, 2018 | $498.0K | Mar 7, 2019 |
| FY2018 | Jun 30, 2018 | $648.0K | Mar 7, 2019 |
| FY2018 | Mar 31, 2018 | $340.0K | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $487.0K | Mar 7, 2019 |
| FY2018 | Sep 30, 2017 | $523.0K | Mar 7, 2019 |
| FY2018 | Jun 30, 2017 | $438.0K | Mar 7, 2019 |
| FY2018 | Mar 31, 2017 | $475.0K | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $1.89M | Mar 7, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $51.95M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $63.72M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $58.44M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $51.49M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $43.52M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $17.40M | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | $2.26M | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | $829.0K | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | $650.0K | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | $492.0K | Mar 12, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $487.0K | Mar 8, 2018 |
| FY2017 | Sep 30, 2017 | $523.0K | Mar 8, 2018 |
| FY2017 | Jun 30, 2017 | $438.0K | Mar 8, 2018 |
| FY2017 | Mar 31, 2017 | $475.0K | Mar 8, 2018 |
| FY2017 | Dec 31, 2016 | $511.0K | Mar 8, 2018 |
| FY2017 | Sep 30, 2016 | $477.0K | Mar 8, 2018 |
| FY2017 | Jun 30, 2016 | $441.0K | Mar 8, 2018 |
| FY2017 | Mar 31, 2016 | $458.0K | Mar 8, 2018 |
| FY2016 | Dec 31, 2015 | $436.0K | Mar 10, 2017 |
| FY2016 | Sep 30, 2015 | $429.0K | Mar 10, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($265.94M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($193.51M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | ($80.74M) | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | ($71.04M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($6.55M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | ($155.64M) | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | ($26.02M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($18.78M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($24.45M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($17.12M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($270.02M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($171.78M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | ($82.38M) | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | ($78.65M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($78.04M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | ($62.85M) | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | ($21.40M) | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($23.14M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($21.60M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($19.66M) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $197.10M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $127.64M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $61.06M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $53.46M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $50.08M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $28.69M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $41.09M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $36.92M | Mar 12, 2020 |
| FY2019 | Dec 31, 2017 | $30.88M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $27.07M | Mar 7, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($204.88M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($134.68M) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | ($70.23M) | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | ($59.60M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | ($65.55M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | ($53.55M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | ($77.58M) | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | ($49.23M) | Mar 12, 2020 |
| FY2019 | Dec 31, 2017 | ($50.47M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($34.00M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.01M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.29M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $6.09M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $3.72M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $1.19M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $841.0K | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $2.24M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $1.89M | Mar 12, 2020 |
| FY2019 | Dec 31, 2017 | $8.25M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $1.92M | Mar 7, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $808.06M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $457.94M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $252.06M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $149.29M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $204.89M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $261.86M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $78.74M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $73.04M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $55.43M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $74.94M | Mar 8, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $153.75M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $142.59M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $160.93M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $113.91M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $116.89M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $185.77M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $82.37M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $37.17M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $29.28M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $22.93M | Mar 8, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $654.31M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $315.34M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $91.13M | Feb 5, 2026 |
| FY2025 | Dec 31, 2022 | $35.38M | Feb 5, 2026 |
| FY2024 | Dec 31, 2021 | $88.00M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | $76.10M | Mar 11, 2024 |
| FY2022 | Dec 31, 2019 | ($3.63M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2018 | $35.88M | Feb 28, 2022 |
| FY2019 | Dec 31, 2017 | $26.15M | Mar 12, 2020 |
| FY2019 | Dec 31, 2016 | $52.01M | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.16B) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($891.08M) | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | ($697.58M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($616.84M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($545.80M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($539.25M) | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($383.62M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($297.24M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($237.27M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($173.88M) | Mar 8, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $737.06M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $392.10M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $195.81M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $102.30M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $164.16M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $228.06M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $54.44M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $54.06M | Mar 12, 2020 |
| FY2019 | Dec 31, 2017 | $41.54M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $32.94M | Mar 7, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 12, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | (1) | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | (2) | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | 0 | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | 0 | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | 0 | Mar 12, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 215.93M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 157.75M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | 114.96M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 77.20M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 76.73M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 76.00M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 50.33M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 41.52M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 29.66M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 25.02M | Mar 8, 2018 |